Tag
A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most fro
Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Pers
This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel thera
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
Recent data from the ARIC study and emerging expert consensus are redefining primary aldosteronism. Rather than a rare, all-or-nothing condition, it is now viewed as a broad spectrum where even subclinical elevations significantly increase
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
The SCENA-AF trial highlights the efficacy of nanosecond pulsed field ablation (nsPFA) for treating paroxysmal atrial fibrillation, achieving an 88.49% success rate at 12 months with minimal complications and a significant shift toward loca
The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.
The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a
A massive UK Biobank study demonstrates that combining serum metabolomics with polygenic risk scores and clinical data significantly improves the prediction of incident atrial fibrillation, identifying key metabolic markers like linoleic ac
A large-scale individual patient data meta-analysis reveals that while systemic embolic events are less common than strokes in atrial fibrillation, they carry an equivalent mortality risk. NOACs significantly reduce this risk by 29% compare
The NURSECAT-AF trial demonstrates that structured nurse-led care significantly improves quality of life and reduces arrhythmia recurrence and emergency visits by 80% in patients undergoing their first catheter ablation for atrial fibrillat
The DECAF randomized trial challenges the traditional view of caffeine as a trigger for atrial fibrillation, demonstrating that coffee consumption significantly reduces arrhythmia recurrence after cardioversion compared to total abstinence.
A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al
This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra
This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a
The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, of
The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the
A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potent
This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFp
